National Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
ICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
NPJ Biofilms Microbiomes. 2022 Aug 24;8(1):67. doi: 10.1038/s41522-022-00330-y.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has posed multiple challenges to global public health. Clinical features and sequela of SARS-CoV-2 infection include long-term and short-term complications often clinically indistinguishable from bacterial sepsis and acute lung infection. Post-hoc studies of previous SARS outbreaks postulate secondary bacterial infections with microbial dysbiosis. Oral microbial dysbiosis, particularly the altered proportion of Firmicutes and Proteobacteria, observed in other respiratory virus infection, like influenza, has shown to be associated with increased morbidity and mortality. Oropharynx and lung share similar kinds of bacterial species. We hypothesized that alteration in the Human Oropharyngeal Microbiome in SARS-CoV-2 patients can be a clinical indicator of bacterial infection related complications. We made a longitudinal comparison of oropharyngeal microbiome of 20 SARS-CoV-2 patients over a period of 30 days; at three time points, with a 15 days interval; contrasting them with a matched group of 10 healthy controls. Present observation indicates that posterior segment of the oropharyngeal microbiome is a key reservoir for bacteria causing pneumonia and chronic lung infection on SARS-CoV-2 infection. Oropharyngeal microbiome is indeed altered and its α-diversity decreases, indicating reduced stability, in all SARS-CoV-2 positive individuals right at Day-1; i.e. within ~24 h of post clinical diagnosis. The dysbiosis persists long-term (30 days) irrespective of viral clearance and/or administration of antibiotics. There is a severe depletion of commensal bacteria phyla like Firmicutes among the patients and that depletion is compensated by higher proportion of bacteria associated with sepsis and severe lung infection from phyla Proteobacteria. We also found elevated proportions of certain genus that have previously been shown to be causal for lung pneumonia in studies of model organisms and human autopsies' including Stenotrophomonas, Acenetobactor, Enterobactor, Klebsiella and Chryseobacterium that were to be elevated among the cases. We also show that responses to the antibiotics (Azithromycin and Doxycycline) are not uniform for all individuals.
严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)大流行对全球公共卫生造成了多重挑战。SARS-CoV-2 感染的临床特征和后遗症包括长期和短期并发症,这些并发症通常与细菌性败血症和急性肺部感染难以区分。先前 SARS 爆发的事后研究推测存在继发性细菌感染和微生物失调。其他呼吸道病毒感染(如流感)中观察到的口腔微生物失调,特别是厚壁菌门和变形菌门的比例改变,与发病率和死亡率增加有关。口咽和肺部具有相似的细菌种类。我们假设 SARS-CoV-2 患者口咽微生物组的改变可能是与细菌感染相关并发症的临床指标。我们对 20 例 SARS-CoV-2 患者的口咽微生物组进行了 30 天的纵向比较;在三个时间点,间隔 15 天;并将其与 10 名健康对照组进行对比。目前的观察表明,在后咽部的口咽微生物组是导致 SARS-CoV-2 感染后肺炎和慢性肺部感染的细菌的关键储存库。口咽微生物组确实发生了改变,其 α 多样性降低,表明所有 SARS-CoV-2 阳性个体在第 1 天(即临床诊断后约 24 小时内)就出现了稳定性降低。无论病毒清除和/或使用抗生素,这种失调都会长期(30 天)持续存在。患者中厚壁菌门等共生菌门的数量严重减少,而这种减少被来自变形菌门的与败血症和严重肺部感染相关的细菌的更高比例所补偿。我们还发现,某些属的比例升高,这些属在模型生物和人类尸检研究中被证明与肺部肺炎有关,包括在病例中升高的 Stenotrophomonas、Acenetobactor、Enterobactor、Klebsiella 和 Chryseobacterium。我们还表明,对阿奇霉素和多西环素的抗生素反应并非对所有个体都一致。